Gapping up
In reaction to strong earnings/guidance: UIS +18.7%, IRBT +13.3%, SIX +10.3%, (also increases quarterly dividend to $0.52 from $0.47/share), SMCI +7.6%, AWRE +6.3%, BRCM +5.6%, MANH +4.9%, YHOO +4.7%, NBR +3.9%, SONC +3.5%, DOW +3.3%, CBST +2.3%, GSK +2%, IBKR +1.9%, ISRG +1.8%, HA +1.5%, XRX +1.4%, USB +1.4%, ABT +1.4%, RHI +1.3%, ABB +0.9%, .
M&A news: BTUI +79.7% (Amtech (ASYS) to acquire BTU International in an all-stock transaction)
Other news: BBLU +22.5% (CEO responded to 'false statements and allegations made by the Pump Stopper' in Seeking Alpha), RPRX +14.6% (results from long-term study of Androxal exhibit positive safety profile), ROYL +13.8% (confirms new high rate well), TKMR +12.2% (provides periodic update on TKM-Ebola program), IBIO +8% (cont volatility pre-mkt), NVDQ +7.3% (appoints Mizuho Medical as PINPOINT distributor for Japan), CLF +5.3% (still checking), LXRX +5.2% (Lexicon Pharma and Ipsen (IPSEY) enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate), GWPH +4.4% (announces Epidiolex receives Orphan designation from European Medicines Agency for the treatment of Dravet Syndrom), GSAT +4% (cont volatility pre-mkt), CLMT +2.6% (declared quarterly cash distribution of $0.685 per unit, unchanged from prior quarter), FUN +2.1% (following SIX results), NLNK +1.8% (CEO appeared on CNBC's Fast Money; said early halt to IMPRESS trial in pancreatic cancer is possible), GEVA +1.3% ( starts rolling submission of a biologics license application to the FDA For Sebelipase Alfa), YELP +1.3% (ahead of earning later today), JNJ +1.2% (announces major commitment to speed ebola vaccine development and significantly expand production)
Analyst comments: AOL +2.3% (upgraded to Buy from Hold at Evercore), HES +2% (upgraded to Buy from Neutral at UBS), DF +1.9% (upgraded to Overweight from Equal-Weight at Morgan Stanley), GNRC +1.6% (upgraded to Buy from Hold at KeyBanc Capital Mkts), GRPN +1.3% (initiated with a Buy at Brean Capital), CHK +1.2% (upgraded to Buy from Neutral at UBS), STLD +0.9% (upgraded to Outperform from Neutral at Macquarie), CHUY +0.5% (upgraded to Buy at Stifel)